Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
Epistemonikos ID: 8fbd075390dacb6d12d780be0255358b2c032873
First added on: May 20, 2024